论文部分内容阅读
目的:观察升血颗粒联合化疗治疗进展期胃癌的疗效和毒副作用。方法:70例进展期胃癌患者随机分为升血颗粒加化疗组(治疗组)35例和单纯化疗组(对照组)35例。结果:治疗组中完全缓解(CR)1例(2.8%),部分缓解(PR)16例(45.7%),稳定(SD)11例(31.4%),进展(PD)7例(20.0%),有效(RR=CR+PR)17例(48.6%);对照组中,PR 14例(40.0%),SD 9例(25.7%),PD12例(34.3%),RR 14例(40.0%)。治疗组RR高于对照组,但2组比较,差异无显著性意义(P>0.05)。治疗组临床证候改善率为82.35%,对照组为37.50%,治疗组明显高于对照组(P<0.05),提示升血颗粒能显著改善晚期胃癌患者的临床症状。治疗组治疗后CD3、CD4/CD8比值明显高于对照组(P<0.05)。提示升血颗粒具有增效减毒功能。治疗组Karnvfsky评分提高和稳定的比例为80.0%,对照组为42.9%,2组比较,差异有显著性意义(P<0.05)。骨髓抑制:治疗组白细胞减少、血小板减少、血红蛋白下降患者例数各分级程度均较对照组少;消化道不良反应:治疗组为31.4%,对照组为54.3%,2组比较,差异有显著性意义(P<0.05)。结论:升血颗粒配合化疗可显著改善进展期胃癌患者的临床症状,提高生存质量。
Objective: To observe the effect and side effects of Shengxue granule combined with chemotherapy on advanced gastric cancer. Methods: Seventy patients with advanced gastric cancer were randomly divided into Shengxue granule plus chemotherapy group (treatment group) 35 cases and chemotherapy alone group (control group) 35 cases. Results: One case (2.8%) of complete remission (CR), 16 cases (45.7%) of partial remission (PR), 11 cases of stable (SD) and 7 cases of progressive (PD) (RR = CR + PR) in 17 cases (48.6%). In the control group, PR was 14 (40.0%), SD was 9 (25.7%), PD was 12 (34.3% . RR in the treatment group was higher than that in the control group, but there was no significant difference between the two groups (P> 0.05). The improvement rate of clinical syndrome in treatment group was 82.35%, while that in control group was 37.50%. The treatment group was significantly higher than that in control group (P <0.05), which indicated that Shengxue Granule could significantly improve the clinical symptoms of patients with advanced gastric cancer. After treatment, the ratio of CD3 and CD4 / CD8 in the treatment group was significantly higher than that in the control group (P <0.05). Prompt Shengxue particles with synergistic attenuation function. The Karnvfsky score increased and stabilized in the treatment group was 80.0% compared with 42.9% in the control group. There was significant difference between the two groups (P <0.05). Myelosuppression: The treatment group leukopenia, thrombocytopenia, hemoglobin cases decreased the number of grading than the control group less; gastrointestinal adverse reactions: the treatment group was 31.4%, 54.3% in the control group, the two groups, the difference was significant Significance (P <0.05). Conclusion: Shengxue granule combined with chemotherapy can significantly improve the clinical symptoms of patients with advanced gastric cancer and improve the quality of life.